JAK2 inhibitor appears effective in myelofibrosis

Описание к видео JAK2 inhibitor appears effective in myelofibrosis

From Healio.com, Moshe Talpaz, MD, associate chief of the division of hematology/oncology at the University of Michigan Comprehensive Cancer Center, discusses results of a phase 2 study of SAR302503, an investigational selective JAK2 inhibitor. The findings suggest the treatment was associated with reductions in spleen size and improved constitutional symptoms in patients with high-risk primary or secondary myelofibrosis.

Комментарии

Информация по комментариям в разработке

Похожие видео